|
|
| | LORAZEPAM-D4 Basic information |
| Product Name: | LORAZEPAM-D4 | | Synonyms: | LORAZEPAM-D4;2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(6-chlorophenyl-2,3,4,5-d4)-1,3-dihydro-3-hydroxy-;LORAZEPAM-D4,100/MLINACETONITRILE;Lorazepam-d4 solution;7-chloro-5-(2-chloro-3,4,5,6-tetradeuteriophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one;LORAZEPAM (D4, 98%) 1.0 MG/ML IN ACETONITRILE;LORAZEPAM (D4, 98%) 100 UG/ML IN ACETONITRILE;Lorazepam-d4 (CRM) | | CAS: | 84344-15-0 | | MF: | C15H10Cl2N2O2 | | MW: | 321.16 | | EINECS: | 200-835-2 | | Product Categories: | | | Mol File: | 84344-15-0.mol |  |
| | LORAZEPAM-D4 Chemical Properties |
| Fp | 2℃ | | storage temp. | -20°C | | solubility | DMSO: Soluble: =10 mg/ml
Ethanol: Sparingly soluble: 1-10 mg/ml |
| | LORAZEPAM-D4 Usage And Synthesis |
| Uses | Lorazepam-d4 is labelled Lorazepam (L469850) which is a high-potency, intermediate-duration, 3-hydroxy benzodiazepine drug, It is often used to treat anxiety disorders. | | References | [1] L G MILLER. Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acidA receptor function.[J]. Journal of Pharmacology and Experimental Therapeutics, 1988, 246 1: 170-176.
[2] DAVID BALDWIN. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis.[J]. BMJ : British Medical Journal, 2011: d1199. DOI: 10.1136/bmj.d1199
[3] BJOERN MOOSMANN Volker A Philippe Bisel. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics[J]. Drug Testing and Analysis, 2014, 6 7-8: 757-763. DOI: 10.1002/dta.1628 |
| | LORAZEPAM-D4 Preparation Products And Raw materials |
|